Rhythm Pharmaceuticals to Present at Bank of America Merrill Lynch 2019 Health Care Conference
May 07 2019 - 8:00AM
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical
company focused on the development and commercialization of
therapeutics for the treatment of rare genetic disorders of
obesity, today announced that Keith Gottesdiener, M.D., Chief
Executive Officer of Rhythm, will participate in a fireside chat at
the Bank of America Merrill Lynch 2019 Health Care Conference on
Tuesday, May 14, 2019 at 1:00 p.m. PT (4:00 p.m. ET) in Las Vegas,
NV.
A live audio webcast of the presentation will be available under
“Events & Presentations” in the Investors & Media section
of the Company’s website at www.rhythmtx.com. A replay of the
webcast will be available on the Rhythm website for 30 days
following the presentation.
About Rhythm
Rhythm is a biopharmaceutical company focused on the development
and commercialization of therapies for the treatment of rare
genetic disorders of obesity. Rhythm is currently evaluating the
efficacy and safety of setmelanotide, the company’s first-in-class
MC4R agonist, in Phase 3 studies in patients with POMC deficiency
obesity, LEPR deficiency obesity, BBS, and Alström syndrome. Rhythm
is dedicated to improving the understanding of severe obesity that
results from specific genetic disorders. For healthcare
professionals, visit www.UNcommonObesity.com for more
information. For patients and caregivers,
visit www.LEADforRareObesity.com for more information.
The company is based in Boston, MA.
Investor Contact:Hannah DeresiewiczStern
Investor Relations,
Inc.212-362-1200hannah.deresiewicz@sternir.com
Media Contact:Adam DaleyBerry & Company
Public Relations212-253-8881adaley@berrypr.com
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Jul 2023 to Jul 2024